Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 34 of 37 for:    Acerta Pharma

US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI) (PROXY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04125290
Recruitment Status : Not yet recruiting
First Posted : October 14, 2019
Last Update Posted : October 14, 2019
Sponsor:
Collaborator:
Iqvia Pty Ltd
Information provided by (Responsible Party):
AstraZeneca

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Not yet recruiting
Estimated Primary Completion Date : September 11, 2023
Estimated Study Completion Date : September 11, 2023
Publications:
Kreitman 2018, Leukemia https://doi.org/10.1038/s41375-018-0210-1